Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?
Open Access
- 25 March 2022
- journal article
- research article
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-9
Abstract
A high Mandard score may indicate the tumor is insensitive to chemotherapy. We analyzed tumor regression and lymph node response under different Mandard scores to assess the impact of Mandard score on prognosis. Methods. Mandard scores and ypN stage of postoperative pathological reports were recorded. The results were reviewed by a professional pathologist. The radiologist compared the tumor regression before and after chemotherapy by computed tomography (CT). The survival of all patients was obtained by telephone follow-up. Multivariate Cox regression was used to assess the relationship between overall risk of death and Mandard score, imaging evaluation, and ypN stage. Results. In the Mandard score (4-5) group, the median survival time for PR and ypN0 patients was 68.5 and 76.7 months. While in the Mandard score (1-2) group, the median survival time for PD and ypN3a patients was 15.6 and 14.5 months. Imaging evaluation of tumor regression (PR 68.5 months, SD 27.8 months, and PD 10.2 months) and lymph node remission (ypN0 76.7 months, ypN1 61.6 months, ypN2 18.0 months, ypN3a 18.7 months, and ypN3b 18.3 months) showed improved survival. Mandard score, imaging evaluation, and ypN stage are important prognostic factors affecting prognosis. Conclusion. A high Mandard score does not mean neoadjuvant chemotherapy is ineffective in gastric cancer. Patients with imaging evaluation of tumor regression and ypN stage reduction may benefit from neoadjuvant chemotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82072734)
This publication has 31 references indexed in Scilit:
- Mandard Tumour Regression Grade, Perineural Invasion, Circumferential Resection Margin and Post-chemoradiation Nodal Status Strongly Predict Outcome in Locally Advanced Rectal Cancer Treated with Preoperative ChemoradiotherapyClinical Oncology, 2014
- Tumor Volume of Resectable Adenocarcinoma of the Esophagogastric Junction at Multidetector CT: Association with Regional Lymph Node Metastasis and N StageRadiology, 2013
- Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III TrialJournal of Clinical Oncology, 2011
- Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancerEuropean Journal of Cancer, 2011
- Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954Journal of Clinical Oncology, 2010
- Comparative lesion sequencing provides insights into tumor evolutionProceedings of the National Academy of Sciences, 2008
- American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal AdenocarcinomaJournal of Clinical Oncology, 2007
- Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal CancerAnnals of Surgery, 2005
- Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiationCancer, 2005
- Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapyCancer, 2003